Tirzepatide 10mg vial

GLP-1 / incretin

What is Tirzepatide?

Last updated: 29 October 2026

A dual GIP and GLP-1 receptor agonist (LY3298176). A reference compound for comparing dual and single incretin activity.

Dual GIP / GLP-1 agonistClinically studied
Class
Dual GIP / GLP-1 receptor agonist
Also known as
LY3298176
Type
39-amino-acid acylated peptide
Research stage
Extensively studied in clinical trials

01 · Classification

What it is

Tirzepatide is a 39-amino-acid synthetic peptide with a C20 fatty diacid side chain. Its sequence is based on native GIP, and it is engineered to also activate the GLP-1 receptor.

It is widely used as a reference compound in incretin research, because a large body of published trial data exists to compare new findings against.

02 · Mechanisms

What has been studied

  • GIP receptor: tirzepatide has relatively high affinity for the GIP receptor, which is a focus of research into why dual agonists behave differently from GLP-1-only compounds.
  • GLP-1 receptor: studied for glucose-dependent insulin release, gastric emptying and central appetite signalling.
  • Biased signalling: published work suggests it favours cAMP signalling over beta-arrestin recruitment at the GLP-1 receptor, a topic of ongoing mechanistic research.

03 · Evidence

Where the research is

Large phase 3 programmes have been published. Pharmaceutical formulations are regulated medicines. The research-grade peptide sold here is a laboratory reagent and is not a medicine.

04 · Primary sources

Read the literature

Search the primary research record directly rather than relying on summaries, including this one.

Research use only

Supplied strictly for laboratory and educational research. Not a drug, not for human or veterinary use, and not evaluated by the FDA. This overview is not medical advice and gives no dosing or administration guidance.

← All research overviews